What is the new drug for myositis? Exploring Breakthroughs and Emerging Treatments
•
3 min read
For years, patients with myositis relied on older immunosuppressants and corticosteroids, but the landscape is rapidly evolving with new, targeted therapies. A key advancement is Octagam 10% (Intravenous Immunoglobulin or IVIg), which received FDA approval in 2021 specifically for adult dermatomyositis. This milestone highlights significant progress in answering the question, 'What is the new drug for myositis?'
